To change the lives of children with cancer through funding impactful research, raising awareness, supporting families, and empowering everyone to help cure childhood cancer.
Alex's Lemonade Stand Foundation (ALSF) emerged from the front yard lemonade stand of 4-year-old Alexandra “Alex” Scott, who was fighting cancer and wanted to raise money to find cures for all children with cancer. Her spirit and determination inspired others to support her cause, and when she passed away at the age of 8, she had raised $1 million. Since then, the Foundation bearing her name has evolved into a national fundraising movement and is one of the leading funders of pediatric cancer research in the U.S. and Canada.
Nick Gilger always tells people that, without ALSF, he would not have a family. And it's true. Emily, mom to neuroblastoma survivor Edie, battled neuroblastoma while pregnant with her son Kinsey. Both Edie and Emily were treated with the same breakthrough treatment made possible by ALSF-funded research.
ALSF funds research every step of the way—from early stage innovative research all the way through to lifesaving clinical trials for kids with cancer. ALSF is the only childhood cancer research organization with the NCI peer-reviewed funder designation for rigorous selection of research grants.
The mission of ALSF’s Travel For Care program is to ensure children battling childhood cancer have the financial assistance needed to travel to clinical trials, experimental therapeutics, or treatment innovations not currently available at their local institution.
The needs of childhood cancer families don’t stop during a pandemic. Many already operated on one income and now face more economic uncertainty. But they still need to travel for treatment, get groceries for their families and find safe lodging near hospitals to socially distance. This emergency fund helps families respond to these needs to during this critical time.
Center of Excellence grants are given to institutions over a 5-year period to support research as well as the acceleration of clinical trials. The program accomplishes these goals by funding infrastructure needs and training the next generation of leaders in preclinical and clinical drug development.